Belite Bio, Inc (BLTE) fair value analysis
Nasdaq · Updated 2026-09-07
Belite Bio, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, particularly age-related macular degeneration and other inherited retinal conditions. The company operates in the United States and conducts research and development activities for its pipeline of investigational drug candidates.
Valuation status
Awaiting full valuationBLTE does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $154.79
- Sector
- Healthcare
- 12-month range
- $73.50–$177.58
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- 50/200-day trend
- Mixed
- 52-week position
- The top quarter of its range
What our data shows for BLTE
- Shares are trading in the upper third of their 12-month price range of $73.50–$177.58.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BLTE
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
What people are saying
Follow the BLTE conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — # BLTE Weekly Indicator Summary TickrTrends' derived indicators for BLTE show a shift in the 50/200-day trend state this week, moving from an uptrend to a mixed trend. The healthcare sector stock's valuation assessment remains in an awaiting full valuation status. These changes reflect evolving price momentum dynamics as tracked by the technical analysis framework.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BLTE stock undervalued?
BLTE does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is BLTE's TickrTrends verdict?
BLTE is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is BLTE overbought or oversold?
TickrTrends does not currently publish an RSI signal for BLTE.